UPB
NASDAQ · Biotechnology
Upstream Bio Inc
$9.47
+1.02 (+12.07%)
Financial Highlights (FY 2026)
Revenue
2.50M
Net Income
-66,105,406
Gross Margin
—
Profit Margin
-2,650.0%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 67.3% | 67.3% | 67.3% |
| Operating Margin | -3,281.2% | -2.2% | -2.1% | -2.1% |
| Profit Margin | -2,650.0% | -2.1% | -1.8% | -2.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.50M | 198.99M | 177.59M | 201.20M |
| Gross Profit | — | 134.01M | 119.60M | 135.50M |
| Operating Income | -81,917,349 | -4,424,685 | -3,738,401 | -4,294,140 |
| Net Income | -66,105,406 | -4,151,490 | -3,219,143 | -4,334,728 |
| Gross Margin | — | 67.3% | 67.3% | 67.3% |
| Operating Margin | -3,281.2% | -2.2% | -2.1% | -2.1% |
| Profit Margin | -2,650.0% | -2.1% | -1.8% | -2.2% |
| Rev Growth | — | +14.1% | -5.8% | +19.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 671.96M | 530.13M | 598.50M |
| Total Equity | — | 1.01B | 856.80M | 928.50M |
| D/E Ratio | — | 0.66 | 0.62 | 0.64 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -78,772,051 | -5,330,036 | -5,179,349 | -6,300,639 |
| Free Cash Flow | — | -2,620,505 | -3,332,995 | -3,816,597 |